Underlying Mechanisms and Signs of CRS

Opinion
Video

The panel discusses the mechanisms believed to cause cytokine release syndrome associated with CAR T-cell therapy and the signs and symptoms.

Video content above is prompted by the following question:

  • What are the proposed mechanisms believed to cause cytokine release syndrome (CRS) associated with CAR T-cell therapy?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
MagnetisMM-6 Data Suggest Safety, Manageability of Elranatamab Combo in NDMM

MagnetisMM-6 Data Suggest Safety, Manageability of Elranatamab Combo in NDMM

Ariana Pelosci
June 3rd 2025
Article

Results from part 1 dose level G of the MagnetisMM-6 trial found elranatamab, daratumumab, and lenalidomide to be safe and manageable in NDMM.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Results from the PERSEUS trial support daratumumab plus bortezomib, lenalidomide, and dexamethasone as a standard of care in transplant-eligible NDMM.

Subcutaneous Daratumumab Combo Sustains MRD-Negative Status in NDMM

Russ Conroy
June 3rd 2025
Article

Results from the PERSEUS trial support daratumumab plus bortezomib, lenalidomide, and dexamethasone as a standard of care in transplant-eligible NDMM.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Subgroup data from CARTITUDE-4 suggest that cilta-cel may overcome the poor prognosis associated with some high-risk features in multiple myeloma.

PFS, OS Improve With Cilta-Cel in R/R Multiple Myeloma Subgroups

Kristi Rosa
June 2nd 2025
Article

Subgroup data from CARTITUDE-4 suggest that cilta-cel may overcome the poor prognosis associated with some high-risk features in multiple myeloma.

Belantamab Mafodotin Combo Elicits PFS in R/R Multiple Myeloma

Belantamab Mafodotin Combo Elicits PFS in R/R Multiple Myeloma

Gina Mauro
June 2nd 2025
Article

PFS was improved with belantamab mafodotin triplet for patients with relapsed/refractory multiple myeloma with high-risk cytogenetics.